To include your compound in the COVID-19 Resource Center, submit it here.

FDA approves AbbVie's HCV regimen

FDA approved Viekira Pak from AbbVie Inc. (NYSE:ABBV) with or without ribavirin to treat HCV genotype 1 infection in patients with and without compensated cirrhosis. AbbVie set the WAC for the three direct-acting-antivral (3-DAA) treatment regimen at $83,319 for

Read the full 396 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers